



TEAMO PRODUCTIONS HQ LIMITED

(Formerly known as GI Engineering Solutions Limited)

CIN: L74110DL2006PLC413221

Regd. & Corporate Office : Unit No. 802, 8th Floor, Aggarwal Cyber Plaza-I, Netaji Subhash Place, North West Delhi, Delhi-110034

Tel No: 011-44789583 | Website: www.tphq.co.in | E-mail ID: cs@giesl.in

September 06, 2026

Listing Compliance Department

National Stock Exchange of India Limited

Exchange Plaza,
Bandra-Kurla Complex,
Bandra (East), Mumbai 400051

NSE SYMBOL: TPHQ

Listing Compliance Department

BSE Limited

Phirozee Jeejeebhoy
Towers, Dalal Street, Fort,
Mumbai – 400 001

Scrip Code: 533048

Sub: Intimation regarding completion of dispatch of Notice of 20th AGM and submission of Newspaper Advertisement made in this regard

Dear Sir/Ma'am,

Pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirement) Regulations, 2015, we wish to inform you that the Notice calling 20th Annual General Meeting ("AGM") of the Company has been sent electronically through our RTA i.e. Bigshare Services Private Limited on Saturday, September 05, 2026.

The 'Notice of AGM, E Voting information and Book Closure' has been published in Financial Express and Jansatta newspapers dated September 06, 2026. A copy of the publication in newspapers is attached herewith for your ready reference and record.

The above information is also available on the website of the Company at www.tphq.co.in

You are requested to take the information on record and oblige.

Thanking You,

Yours faithfully,

for Teamo Productions HQ Limited

Mahaan Nadaar
Managing Director
DIN: 03012355

NATIONAL CEREALS PRODUCTS LIMITED

Registered Office: Solan Brewery, District Solan, Himachal Pradesh-173214
Works: Mohan Nagar, Ghaziabad (U.P.)-201007

Ph. No.: Solan Brewery (H.P.) 01792-2302222, Mohan Nagar, Ghaziabad (U.P.) 0120-2657144
Website: <http://www.nationalcereals.com/> E-mail: ncpmohannagar@yahoo.co.in

NOTICE TO THE SHAREHOLDERS FOR THE 78TH ANNUAL GENERAL MEETING TO BE HELD THROUGH VIDEO CONFERENCING ('VC')/ OTHER AUDIO-VISUAL MEANS ('OAVM')

Notice is hereby given that the 78th Annual General Meeting ('AGM') of National Cereals Products Limited is scheduled to be held on **Saturday, 26th September 2026, at 02:00 PM (IST)**, through Video Conference ('VC')/ Other Audio-Visual Means ('OAVM'), to transact the businesses as set out in the Notice calling 78th AGM in due compliance with the provisions of the Companies Act, 2013, read with Rules and Regulations made thereunder and SEBI (LODR) Regulations 2015, and other applicable circulars issued in this regard. The deemed venue of the AGM shall be the Registered office of the Company at Solan Brewery, Solan, Himachal Pradesh-173214.

In compliance with the applicable circulars, electronic copies of the Notice of the 78th AGM and Annual Report 2025-26 have been sent to all the members whose email IDs are registered with the Company/Depository Participant(s). These documents are also available on the website of the Company at <http://www.nationalcereals.com/> and on the website of stock exchange at <http://www.cse-india.com> and on the website of CDCL at <https://www.evotingindia.com>. (Notice of AGM).

The Members can attend and participate in the AGM through the VC/OAVM facility ONLY, the details of which is provided by the Company in the Notice calling 78th AGM. Accordingly, please note that no provision has been made to attend and participate in the 78th AGM of the Company in person to ensure due compliance with the applicable directives issued by the Government authorities. Members attending the Meeting through VC/OAVM shall be counted for the purpose of reckoning the quorum under Section 103 of the Companies Act, 2013.

Pursuant to Section 108 of the Companies Act, 2013, read with Rule 20 of the Companies (Management and Administration) Rules, 2014, and Regulation 44 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and other applicable laws, the Company is pleased to provide the facility to the Members to exercise their right to vote by electronic means (remote e-voting before the AGM and e-voting during the AGM) on the business to be transacted at the AGM and for this purpose, the Company has appointed CDCL to facilitate voting through electronic means.

A person whose name is recorded in the Register of Members or in the Register of Beneficial Owners maintained by the depositories as on the cut-off date i.e., **19th September 2026, Saturday**, shall only be entitled to avail the facility of remote e-voting before the AGM or e-voting during the AGM. The remote e-voting period commences on **September 23, 2026, Wednesday at 09:00 AM and ends on September 25, 2026 Friday at 05:00 PM**. The remote e-voting module will be disabled by CDCL thereafter and Members will not be allowed to vote electronically beyond the said date and time.

The voting rights of the Members shall be in proportion to their share of the paid-up equity share capital of the Company as on Cut-Off Date i.e., **19th September 2026, Saturday**. The facility of e-Voting shall also be made available during the Meeting and the Members attending the AGM who have not cast their votes by remote e-Voting shall be eligible to cast their votes through e-Voting during the AGM. The Members who already have cast their votes by remote e-Voting prior to the AGM will have right to participate at the AGM but shall not be entitled to cast their votes again at the AGM.

Any person holding shares in physical form and non-individual shareholders, who acquires shares of the Company and becomes a Member of the Company after the dispatch of this Notice and holding shares as on the cut-off date may obtain the user id and password for e-Voting by following the instructions given in the notice calling AGM. For any help or guidance regarding attending the meeting through VC/OAVM and remote e-voting and e-voting during AGM, the member may refer detailed instructions given in the Notice calling AGM. The dispatch of Annual Report including notice of AGM has been completed on September 5, 2026 using electronic means i.e., e-mail.

CS Ashutosh Kumar Pandey, Practicing Company Secretary (Membership No. FCS 6847, CP NO. 7385) has been appointed as the Scrutinizer to scrutinize the e-Voting process (remote e-Voting before the AGM and e-voting during the AGM) in a fair and transparent manner.

NOTICE is further given pursuant to Section 91 of the Companies Act, 2013 that the Register of Members and Share Transfer books will remain closed from **Wednesday, September 23, 2026 to Saturday, September 26, 2026** (both days inclusive), for taking record on the Shareholdings at the Annual General Meeting.

For **NATIONAL CEREALS PRODUCTS LIMITED**
Sol
(CHITRANSHU SHUKLA)
COMPANY SECRETARY

Place: Solan Brewery (H.P.)
Dated: September 5, 2026

THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES ONLY AND IS NOT A PROSPECTUS ANNOUNCEMENT AND DOES NOT CONSTITUTE AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE TO SECURITIES. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION DIRECTLY OR INDIRECTLY OUTSIDE INDIA. INITIAL PUBLIC OFFERING OF EQUITY SHARES OF IBERIA PHARMACEUTICALS INDIA LIMITED ON THE MAIN BOARD OF BSE LIMITED ("BSE") AND NATIONAL STOCK EXCHANGE OF INDIA LIMITED ("NSE"), AND TOGETHER WITH BSE, THE "STOCK EXCHANGE") IN COMPLIANCE WITH CHAPTER II OF THE SECURITIES AND EXCHANGE BOARD OF INDIA (ISSUE OF CAPITAL AND DISCLOSURE REQUIREMENT) REGULATIONS, 2018 AS AMENDED ("SEBI ICDR REGULATIONS")



Please scan the QR Code to view the DRHP and Draft Abridged Prospectus



IBERIA PHARMACEUTICALS INDIA LIMITED

(Previously Known as Iberia Pharmaceuticals India Private Limited)

CIN: U21002DL2013PLC250040

Our Company was originally incorporated as 'Satnam Medical Agencies Private Limited' as a private limited company under the Companies Act, 1956, pursuant to a certificate of incorporation dated March 30, 2013, issued by the Registrar of Companies, National Capital Territory of Delhi and Haryana. Subsequently, the name of our Company was changed from 'Satnam Medical Agencies Private Limited' to 'Iberia Pharmaceuticals India Private Limited' by way of shareholders' resolution dated August 11, 2023. Consequently, a certificate of incorporation pursuant to change of name, dated September 18, 2023, was issued to the Company by the Registrar of Companies, Delhi. Thereafter, our Company was converted into a public limited company pursuant to a special resolution passed by our Shareholders on April 8, 2024, and consequently, a fresh certificate of incorporation dated July 15, 2024 was issued by the Registrar of Companies, Central Processing Centre ("CPC") to our Company under its present name i.e., 'Iberia Pharmaceuticals India Limited'. Our Company's Corporate Identity Number U21002DL2013PLC250040.

Registered Office: Property No. 4, Block-C, First Floor, Sector-8, Dwarka, Bagdola, South West Delhi, New Delhi, Delhi, India, 110077
Corporate Office: Unit No. 304-305, 3rd Floor Tower-B, Global Business Park MG Road, DLF QE, Gurgaon, Haryana, India, 122002
Tel: +91 9319728265; **Fax:** N.A.; **Website:** www.iberiapharmaceuticals.com; **E-mail:** cs@iberiapharmaceuticals.com; **Company Secretary and Compliance Officer:** Mr. Raj Kumar

OUR PROMOTERS: MR. NITIN JAIN, MR. RISHABH JAIN, MR. SAURAV OJHA & MRS. SHIVANI JAIN

INITIAL PUBLIC OFFERING OF UP TO 64,75,560 EQUITY SHARES OF FACE VALUE OF ₹ 10 EACH ("EQUITY SHARES") OF IBERIA PHARMACEUTICALS INDIA LIMITED (OUR "COMPANY" OR THE "ISSUER") FOR CASH AT A PRICE OF ₹ [] PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹ [] PER EQUITY SHARE (THE "ISSUE PRICE") AGGREGATING UP TO ₹ [] LAKHS ("THE ISSUE"). THE ISSUE SHALL CONSIST OF []% OF THE POST-ISSUE PAID-UP EQUITY SHARE CAPITAL OF THE COMPANY.

THE FACE VALUE OF THE EQUITY SHARES IS ₹ 10 EACH AND THE ISSUE PRICE IS [] TIMES THE FACE VALUE OF THE EQUITY SHARES. THE PRICE BAND AND THE MINIMUM BID LOT WILL BE DECIDED BY OUR COMPANY IN CONSULTATION WITH THE BOOK RUNNING LEAD MANAGER AND WILL BE ADVERTISED IN ALL EDITIONS OF THE ENGLISH NATIONAL DAILY NEWSPAPER [], ALL EDITIONS OF THE HINDI NATIONAL DAILY NEWSPAPER [], AND [] EDITION OF [] (HINDI ALSO BEING THE REGIONAL LANGUAGE OF THE STATE WHEREIN THE REGISTERED OFFICE OF OUR COMPANY IS LOCATED) EACH WITH WIDE CIRCULATION, AT LEAST TWO WORKING DAYS PRIOR TO THE BID/ISSUE OPENING DATE AND SHALL BE MADE AVAILABLE TO STOCK EXCHANGES FOR THE PURPOSE OF UPLOADING ON THEIR RESPECTIVE WEBSITES IN ACCORDANCE WITH THE SECURITIES AND EXCHANGE BOARD OF INDIA (ISSUE OF CAPITAL AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2018 (THE "SEBI ICDR REGULATIONS").

In case of any revision in the Price Band, the Bid/Issue Period shall be extended for at least three additional Working Days after such revision of the Price Band, subject to the total Bid/Issue Period not exceeding 10 Working Days. In cases of force majeure, banking strike or similar unforeseen circumstances, our Company, for reasons to be recorded in writing extend the Bid/Issue Period for a minimum of one Working Day, subject to the Bid/Issue Period not exceeding 10 Working Days. Any revision in the Price Band, and the revised Bid/Issue Period, if applicable, shall be widely disseminated by notification to the Stock Exchanges by issuing a press release and also by indicating the change on the website of the BRLM and at the terminals of the Members of the Syndicate and by intimation to Designated Intermediaries and Sponsor Bank.

The Issue is being made through the Book Building Process and is in compliance with Regulation 6(1) of the SEBI ICDR Regulations wherein in terms of Regulation 32(1) of the SEBI ICDR Regulations, not more than 50% of the Net Issue shall be available for allocation on a proportionate basis to Qualified Institutional Buyers ("QIBs", and such portion, the "QIB Portion") provided that our Company, in consultation with the BRLMs, may allocate up to 60% of the QIB Portion to Anchor Investors on a discretionary basis in accordance with the SEBI ICDR Regulations ("Anchor Investor Portion"), of which 33.33% shall be available for allocation to domestic Mutual Funds and 6.67% shall be reserved for Life Insurance Companies and Pension Funds, subject to valid Bids being received from domestic Mutual Funds, Life Insurance Companies and Pension Funds at or above the price at which Equity Shares will be allocated to Anchor Investors ("Anchor Investor Allocation Portion", in accordance with the SEBI ICDR Regulations. In the event of under-subscription or non-allocation in the Anchor Investor Portion, the balance Equity Shares shall be added to the Net QIB Portion. Further, 5% of the Net QIB Portion shall be available for allocation on a proportionate basis only to Mutual Funds and the remainder of the Net QIB Portion shall be available for allocation on a proportionate basis to all QIB Bidders (other than Anchor Investors) including Mutual Funds, subject to valid Bids being received at or above the Issue Price. However, if the aggregate demand from Mutual Funds is less than 5% of the QIB Portion, the balance Equity Shares available for allocation in the Mutual Fund Portion will be added to the remaining QIB Portion for proportionate allocation to QIBs. Further, not less than 15% of the Net Issue shall be available for allocation to Non-Institutional Bidders out of which (a) one-third of such portion shall be reserved for applicants with application size of more than 200,000 and upto 10,00,000; and (b) two-third of such portion shall be reserved for applicants with application size of more than 10,00,000, provided that the unsubscribed portion in either of such sub-categories may be allocated to applicants in the other sub-category of Non-Institutional Bidders and not less than 35% of the Net Issue shall be available for allocation to Retail Individual Bidders (RIBs) in accordance with the SEBI ICDR Regulations ("Retail Portion", subject to valid Bids being received from them at or above the Issue Price. Further, all potential Bidders (except Anchor Investors) are required to mandatorily utilise the Application Supported by Blocked Amount ("ASBA") process by providing details of their respective bank accounts (including UPI ID for UPI Bidders using UPI Mechanism) (as defined hereinafter) in which the Bid amount will be blocked by the SCSBs or the Sponsor Bank, as applicable, to participate in the Issue. Anchor Investors are not permitted to participate in the Anchor Investor Portion of the Issue through the ASBA process. For details, see "Issue Procedure" beginning on page 337 of the DRHP.

This public announcement is being made in compliance with the provisions of Regulation 26(2) of the SEBI ICDR Regulations to inform the public that the Company is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other consideration, to make an initial public offering of its Equity Shares pursuant to the Issue and has filed the DRHP and the Draft Abridged Prospectus on September 05, 2026 with the Stock Exchanges and Securities and Exchange Board of India (SEBI). Pursuant to Regulation 26(1) of the SEBI ICDR Regulations, the DRHP filed with SEBI and the Stock Exchanges has been made public for comments, if any, for a period of at least 21 days from the date of publication of this public announcement by hosting it along with the Draft Abridged Prospectus on the website of SEBI at www.sebi.gov.in, websites of the Stock Exchanges at www.bseindia.com and www.nseindia.com, on the website of the Company at www.iberiapharmaceuticals.com; and on the websites of the Book Running Lead Managers ("BRLM"), i.e. Turnaround Corporate Advisors Private Limited at www.tcagroup.in. The Company invites the public to give their comments on the DRHP filed with SEBI and the Stock Exchanges, with respect to disclosures made in the DRHP. The public is requested to send a copy of the comments to SEBI, to the Company Secretary and Compliance Officer of the Company and/or the BRLMs at their respective addresses mentioned herein. All comments must be received by SEBI and/or our Company and/or the Company Secretary and Compliance Officer of our Company and/or the BRLMs in relation to the Issue on or before 5.00 P.M. on the 21st day from the date of publication of this public announcement.

Investments in equity and equity related securities involve a degree of risk and Bidders should not invest any funds in the Issue unless they can afford to take the risk of losing their entire investment. Bidders are advised to read the risk factors carefully before taking an investment decision in the Issue. For taking an investment decision, Bidders must rely on their own examination of our Company and the Issue, including the risks involved. The Equity Shares in the Issue have neither been recommended, nor approved by SEBI, nor does SEBI guarantee the accuracy or adequacy of the contents of the Draft Red Herring Prospectus. Special attention of the Bidders is invited to "Risk factor" beginning on page 23 of the DRHP.

Any decision to invest in the Equity Shares described in the DRHP may only be taken after the Red Herring Prospectus ("RHP") has been filed with the RoC and must be made solely on the basis of such RHP as there may be material changes in the RHP from the DRHP. The Equity Shares, when issued through the RHP, are proposed to be listed on the Stock Exchanges.

For details of the share capital and capital structure and the names of the signatories of the Memorandum of Association and the number of shares subscribed by them of the Company, please see the section titled "Capital Structure" on page 88 of the DRHP. The liability of the members of the Company is limited by their shares. For details of the main objects of the Company as contained in the Memorandum of Association, please see the section titled "History and Certain Corporate Matters" on page 244 of the DRHP.

BOOK RUNNING LEAD MANAGER	REGISTRAR TO THE ISSUE	COMPANY SECRETARY AND COMPLIANCE OFFICER
 TURNAROUND CORPORATE ADVISORS PRIVATE LIMITED Address: 614, Vishwadeep Building, Plot No. 4 District Centre, Janakpuri-A-3, West Delhi- 110058, India Telephone: +91 8287356934 Email: iberia ipo@Turnaroundmb.com Website: www.tcagroup.in Contact Person: Rajveer Singh SEBI Registration Number: INM000012290	 BIGSHARE SERVICES PRIVATE LIMITED Address: Office No. S-62, 6th floor, Pinnacle Business Park, Next to Ahura Centre, Mahakali Caves Road, Andheri (East), Mumbai -400093 Telephone No.: +91 22 82638200 Email: ipo@bigshareonline.com Website: www.bigshareonline.com Investor grievance: investor@bigshareonline.com Contact Person: Rajesh Kumawat SEBI Registration No.: INR000001385	 Raj Kumar Address: Property No. 4, Block-C, First Floor, Sector-8, Dwarka, Bagdola, South West Delhi, New Delhi, Delhi, India 110077 Telephone: +91 9319728265 Email: cs@iberiapharmaceuticals.com Investors can contact our Company Secretary and Compliance Officer, the Lead Managers or the Registrar to the Issue, in case of any pre-issue or post-issue related problems, such as non-receipt of letters of allotment, non-credit of allotted Equity Shares in the respective beneficiary account, non-receipt of refund orders and non-receipt of funds by electronic mode etc.

All capitalized terms used herein and not specifically defined shall have the same meaning as ascribed to them in the DRHP.

For IBERIA PHARMACEUTICALS INDIA LIMITED
 On Behalf of the Board of Directors
 Sd/-
 Raj Kumar
 Company Secretary and Compliance Officer

Place: Delhi
Date: September 05, 2026

Disclaimer: Iberia Pharmaceuticals India Limited is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to make an initial public offering of its Equity Shares and has filed the DRHP with SEBI and the Stock Exchanges on September 05, 2026. The DRHP along with the Draft Abridged Prospectus is available on the website of SEBI at www.sebi.gov.in, as well as on the websites of the Stock Exchanges i.e. BSE and NSE at www.bseindia.com and www.nseindia.com, respectively, on the website of the Company at www.iberiapharmaceuticals.com; and on the websites of the Book Running Lead Managers ("BRLM"), i.e. Turnaround Corporate Advisors Private Limited at www.tcagroup.in. Any potential Bidders should note that investment in equity shares involves a high degree of risk and for details relating to such risk, see "Risk Factors" on page 23 of the DRHP. Potential Bidders should not rely on the DRHP filed with SEBI and the Stock Exchanges for making any investment decision and should instead rely on the RHP, when filed,

